Andrew James King
CIK 1823187 · View on SEC EDGAR ↗
First SEC filing: May 1, 2025 · Latest: May 1, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | JBIO | A | 247,500 | — | — | 247,500 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 12, 2026 | JBIO | A | 41,250 | — | — | 386,113 Direct | +11.96% | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | JBIO | Stock Option (Right to Buy) | Common Stock (247,500) | $14.81 | Feb. 11, 2036 | 247,500 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| May 1, 2025 | JBIO | Common Stock | 344,863 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy)→ Common Stock (27,589) | 27,589 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy)→ Common Stock (185,398) | 185,398 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy)→ Common Stock (238,894) | 238,894 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy)→ Common Stock (552,709) | 552,709 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
JBIO
Ph.D. President, Research and Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $507,301 | — | — | — | $258,600 | — | — | $4,541,804 |
| 2024 | $313,636 | — | — | — | $89,641 | — | — | $751,605 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.